---
title: 'Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple
  myeloma: a secondary SWOG analysis'
date: '2024-09-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39321347/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240926193913&v=2.18.0.post9+e462414
source: Blood
description: Dexamethasone is a key component of induction for newly diagnosed multiple
  myeloma (NDMM) despite common toxicities including hyperglycemia and insomnia. In
  the randomized ECOG E4A03 trial, dexamethasone 40 milligrams (mg) once weekly was
  associated with lower mortality than higher doses of dexamethasone. However, the
  performance of dexamethasone dose reductions below this threshold with regard to
  progression-free survival (PFS) and overall survival (OS) in NDMM have not been
  ...
disable_comments: true
---
Dexamethasone is a key component of induction for newly diagnosed multiple myeloma (NDMM) despite common toxicities including hyperglycemia and insomnia. In the randomized ECOG E4A03 trial, dexamethasone 40 milligrams (mg) once weekly was associated with lower mortality than higher doses of dexamethasone. However, the performance of dexamethasone dose reductions below this threshold with regard to progression-free survival (PFS) and overall survival (OS) in NDMM have not been ...